Latest Apoptosis Stories
Australian Researchers Astonished to Learn P53 Not Only Seeks and Destroys, But Prevents DALLAS (PRWEB) May 19, 2013 Scientists are on the verge of unraveling the genesis of cancer. By studying the behavior of distorted genes in the malignant microenvironment (inside the body) studies are attempting to recode damaged gene signals so the body’s immune system can search and destroy cancer. But that’s not all. 1 P53 protein has long been the subject of intense investigation because it...
Proteins, unlike diamonds, aren't forever. And when they wear out, they need to be degraded in the cell back into amino acids, where they will be recycled into new proteins. Researchers at Rockefeller University and the Howard Hughes Medical Institute have identified a new way that the cell's protein recycler, the proteasome, takes care of unwanted and potentially toxic proteins, a finding that has implications for treating muscle wasting, neurodegeneration and cancer. The consensus among...
New research reveals how the tumor suppressor p53 is shut down in metastatic melanoma -- and how it can be revived Cancer cells are a problem for the body because they multiply recklessly, refuse to die and blithely metastasize to set up shop in places where they don't belong. One protein that keeps healthy cells from behaving this way is a tumor suppressor named p53. This protein stops potentially precancerous cells from dividing and induces suicide in those that are damaged beyond...
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA. According to the researchers, p53 is highly inducible by radiation. Activation of p53 stabilizes chromosomes by promoting the repair of heterochromatin DNA, which controls the expression of nearby...
A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins. The effectiveness of the therapy lies in its ability to target a pro-survival cell signaling pathway known as PI3K/AKT/mTOR, upon which the leukemia cells have become dependent. In the study, published in the journal Cancer Research, researchers...
SAN FRANCISCO, April 9, 2013 /PRNewswire/ -- Cleave Biosciences announced today it has raised $10 million in an extension of its Series A financing from new investor New Enterprise Associates (NEA), bringing its Series A total to $54 million. In the fall of 2011, Cleave raised $44 million from US Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors, Astellas Venture Management and Osage University Partners to fund the biopharmaceutical company's cancer drug discovery...
Results showing the same signaling enzymes can trigger two different processes in the cell sound a warning to biomedical researchers Stroke, heart attacks and numerous other common disorders result in a massive destruction of cells and tissues called necrosis. It’s a violent event: As each cell dies, its membrane ruptures, releasing substances that trigger inflammation, which in turn can cause more cellular necrosis. A new Weizmann Institute study may help develop targeted therapies for...
IRVINE, Calif., March 14, 2013 /PRNewswire/ -- GeneTex, a leading manufacturer of high-quality antibodies, is pleased to announce that it will be launching new antibodies against phosphorylated Histone H2A.X and p53 designed for use with zebrafish samples. (Photo: http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b) The zebrafish is being increasingly utilized as a model organism to study DNA repair. The zebrafish genome contains nearly all of the genes involved in the...
SUNNYVALE, Calif., Feb. 28, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced that Dr. John W. Commissiong, Chief Scientific Officer, will be presenting data generated in six hydroxydopamine (6-OHDA) rodent models of Parkinson's disease at the 15(th) Annual Meeting...
SUNNYVALE, Calif. and ALACHUA, Fla., Feb. 25, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB:AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced that the companies will be making a joint poster presentation March 6-7, 2013...
